Slide 26 -
|
References Alberts, Bruce, et al. Molecular biology of the cell. New York: Garland Science, 2002.
Brekke, Ole Henrik; Sandlie, Inger. Therapeutic Antibodies for Human Disease at the Dawn of the Twenty-first Century. Nature Reviews. Drug discovery (2003), 2(1), 52-62
Browning, Jeffery L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature reviews. Drug discovery (2006), 5(7), 564-576
2 Feb. 2007
Patrick, Graham L. An introduction to Medicinal Chemistry. New York: Oxford Press, 2005.
Campbell, Neil A., Reece, Jane B. Biology. San Francisco: Benjamin Cummings,2002.
Casadevall, Arturo; Scharff, Matthew D. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy (1994), 38(8), 1695-1702.
Encyclopedia Britanica. Paul Ehrlich: immunity and the side-chain theory. 20 Apr. 2007
World Health Organization. Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances. (1997)
United States. Federal Drug Administration. Product approval information.1998. 20 Apr. 2007
The Mayo Clinic. Rheumatoid arthritis. 8 Apr. 2002
Cvetkovi’c, Risto S.; Scott, Lesley J.; Adalimumab: a review of its use in adult patients with rheumatoid arthritis. Biodrugs (2006), 20(5), 293-311
Nicolaides, Nicholas C.; Sass, Philip M.; Grasso, Luigi. Monoclonal antibodies: a morphing landscape for therapeutics. Drug Development Research (2006), 67(10), 781-789.
Doan, Tanya; Massarotii, Elena. Rheumatoid arthritis: an overview of new and emerging therapies. J. Clin. Pharmacol. (2005), 45, 751-762
Atarhouch, T.; Hamers, C. Naturally occurring antibodies devoid of light chains. Nature (1993), 363, 464-468
Graninger, Winfried; Smolen, Josef. Treatment of rheumatoid arthritis by TNF-blocking agents. International archives of allergy and immunology (2002), 127(1), 10-14
|